Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 24;11(5):789.
doi: 10.3390/cells11050789.

Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia

Therese Friis  1 , Anna-Karin Wikström  1 , Jesenia Acurio  2   3 , José León  2   3   4 , Henrik Zetterberg  5   6   7   8   9 , Kaj Blennow  5   6 , Maria Nelander  1 , Helena Åkerud  10 , Helena Kaihola  10 , Catherine Cluver  11 , Felipe Troncoso  2 , Pablo Torres-Vergara  3   12 , Carlos Escudero  2   3 , Lina Bergman  1   11   13
Affiliations

Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia

Therese Friis et al. Cells. .

Abstract

Cerebral complications in preeclampsia contribute substantially to maternal mortality and morbidity. There is a lack of reliable and accessible predictors for preeclampsia-related cerebral complications. In this study, plasma from women with preeclampsia (n = 28), women with normal pregnancies (n = 28) and non-pregnant women (n = 16) was analyzed for concentrations of the cerebral biomarkers neurofilament light (NfL), tau, neuron-specific enolase (NSE) and S100B. Then, an in vitro blood−brain barrier (BBB) model, based on the human cerebral microvascular endothelial cell line (hCMEC/D3), was employed to assess the effect of plasma from the three study groups. Transendothelial electrical resistance (TEER) was used as an estimation of BBB integrity. NfL and tau are proteins expressed in axons, NSE in neurons and S100B in glial cells and are used as biomarkers for neurological injury in other diseases such as dementia, traumatic brain injury and hypoxic brain injury. Plasma concentrations of NfL, tau, NSE and S100B were all higher in women with preeclampsia compared with women with normal pregnancies (8.85 vs. 5.25 ng/L, p < 0.001; 2.90 vs. 2.40 ng/L, p < 0.05; 3.50 vs. 2.37 µg/L, p < 0.001 and 0.08 vs. 0.05 µg/L, p < 0.01, respectively). Plasma concentrations of NfL were also higher in women with preeclampsia compared with non-pregnant women (p < 0.001). Higher plasma concentrations of the cerebral biomarker NfL were associated with decreased TEER (p = 0.002) in an in vitro model of the BBB, a finding which indicates that NfL could be a promising biomarker for BBB alterations in preeclampsia.

Keywords: NSE; NfL; S100B; blood-brain barrier; cerebral biomarkers; in vitro studies; preeclampsia; pregnancy; tau.

PubMed Disclaimer

Conflict of interest statement

H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Plasma concentrations of (a) NfL, (b) tau, (c) NSE and (d) S100B. Plasma concentrations of the cerebral biomarkers (a) neurofilament light (NfL), (b) tau, (c) neuron specific enolase (NSE) and (d) S100B in women with preeclampsia (PE), women with normal pregnancies (NP) and non-pregnant women (Non-P). Values are represented by medians with interquartile range (IQR). Pairwise comparisons by Mann-Whitney U-test, Bonferroni correction. * p < 0.05; ** p < 0.01; *** p < 0.001; n.s. = non-significant.
Figure 2
Figure 2
Re−confirmation analysis of TEER and permeability to 70 kDa Dextran. Plasma from a small, randomly chosen sample of the women with preeclampsia (PE, n = 12) and the women with normal pregnancies (NP, n = 13) was analyzed for re−confirmation of previously published data on (a) transendothelial electrical resistance (TEER) and (b) permeability to 70 kDa fluorescein isothiocyanate (FITC)−dextran [30]. ** p < 0.01; **** p < 0.0001.
Figure 3
Figure 3
Association of TEER with NfL, tau, NSE and S100B. Associations between transendothelial electrical resistance (TEER (Ωcm2)) and cerebral biomarkers neurofilament light (NfL (ng/L)), tau (ng/L), neuron-specific enolase (NSE (µg/L)) and S100B (µg/L) in plasma analyzed by a cumulative probability model stratified by group and adjusted for baseline TEER, body mass index, parity and maternal age. NfL p < 0.01, tau p = n.s., NSE p = n.s., S100B p = n.s.
See this image and copyright information in PMC

References

    1. Chappell L.C., Cluver C.A., Kingdom J., Tong S. Pre-eclampsia. Lancet. 2021;398:341–354. doi: 10.1016/S0140-6736(20)32335-7. - DOI - PubMed
    1. Tranquilli A.L., Dekker G., Magee L., Roberts J., Sibai B.M., Steyn W., Zeeman G.G., Brown M.A. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104. doi: 10.1016/j.preghy.2014.02.001. - DOI - PubMed
    1. Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S., Hall D.R., Warren C.E., Adoyi G., Ishaku S., et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72:24–43. doi: 10.1161/HYPERTENSIONAHA.117.10803. - DOI - PubMed
    1. MacKay A.P., Berg C.J., Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet. Gynecol. 2001;97:533–538. doi: 10.1016/s0029-7844(00)01223-0. - DOI - PubMed
    1. Say L., Chou D., Gemmill A., Tuncalp O., Moller A.B., Daniels J., Gulmezoglu A.M., Temmerman M., Alkema L. Global causes of maternal death: A WHO systematic analysis. Lancet Glob. Health. 2014;2:e323–e333. doi: 10.1016/S2214-109X(14)70227-X. - DOI - PubMed

Publication types

Substances